Illumina, Inc. and FlowJo, LLC, has announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single cell analysis, will develop a new software application.

It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina's Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.

Also read: Illumina files patent infringement suit against Genoma SA

"We are excited to partner with Illumina on this project to bring new tools for analyzing and visualizing NGS data to cell biology," said Dr Michael Stadnisky, CEO of FlowJo, LLC. "The new offering will enhance the power of single cell biology research by empowering robust exploration of data from Illumina next-generation sequencing runs."

"FlowJo, LLC is recognized for delivering reliable, high-quality and easy-to-use software solutions that allow cell biologists to study phenotype in individual cells by flow cytometry," said Rob Brainin, Vice President and General Manager, Applied Genomics at Illumina. "We look forward to enabling our customers to bring these trusted FlowJo analytical capabilities to their next-generation sequencing data."

The software will complement the end-to-end commercial solution for high-throughput sequencing of single cells that Illumina announced it is co-developing in partnership with Bio-Rad Laboratories, Inc.

The companies expect the software to be available in Q1 2017.